Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
The search for novel proline analogs for viscosity reduction and stabilization of highly concentrated monoclonal antibody solutions
ID
Prašnikar, Monika
(
Author
),
ID
Proj, Matic
(
Author
),
ID
Bjelošević Žiberna, Maja
(
Author
),
ID
Lebar, Blaž
(
Author
),
ID
Knez, Benjamin
(
Author
),
ID
Kržišnik, Nika
(
Author
),
ID
Roškar, Robert
(
Author
),
ID
Gobec, Stanislav
(
Author
),
ID
Grabnar, Iztok
(
Author
),
ID
Žula, Aleš
(
Author
),
ID
Ahlin Grabnar, Pegi
(
Author
)
PDF - Presentation file,
Download
(6,86 MB)
MD5: 8F36BC87E9F56EBECB0C3E3F62BFD783
URL - Source URL, Visit
https://www.sciencedirect.com/science/article/pii/S0378517324002898
Image galllery
Abstract
Administration of monoclonal antibodies (mAbs) is currently focused on subcutaneous injection associated with increased patient adherence and reduced treatment cost, leading to sustainable healthcare. The main bottleneck is low volume that can be injected, requiring highly concentrated mAb solutions. The latter results in increased solution viscosity with pronounced mAb aggregation propensity because of intensive protein-protein interactions. Small molecule excipients have been proposed to restrict the protein-protein interactions, contributing to reduced viscosity. The aim of the study was to discover novel compounds that reduce the viscosity of highly concentrated mAb solution. First, the chemical space of proline analogs was explored and 35 compounds were determined. Viscosity measurements revealed that 18 proline analogs reduced the mAb solution viscosity similar to or more than proline. The compounds forming both electrostatic and hydrophobic interactions with mAb reduced the viscosity of the formulation more efficiently without detrimentally effecting mAb physical stability. A correlation between the level of interaction and viscosity-reducing effect was confirmed with molecular dynamic simulations. Structure rigidity of the compounds and aromaticity contributed to their viscosity-reducing effect, dependent on molecule size. The study results highlight the novel proline analogs as an effective approach in viscosity reduction in development of biopharmaceuticals for subcutaneous administration.
Language:
English
Keywords:
proline analogs
,
monoclonal antibodies
,
subcutaneous administration
,
viscosity reducers
,
high concentration
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FFA - Faculty of Pharmacy
Publication status:
Published
Publication version:
Version of Record
Year:
2024
Number of pages:
13 str.
Numbering:
Vol. 655, art. 124055
PID:
20.500.12556/RUL-155599
UDC:
615.4:54
ISSN on article:
0378-5173
DOI:
10.1016/j.ijpharm.2024.124055
COBISS.SI-ID:
191471875
Publication date in RUL:
08.04.2024
Views:
373
Downloads:
102
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
International journal of pharmaceutics
Shortened title:
Int. j. pharm.
Publisher:
Elsevier
ISSN:
0378-5173
COBISS.SI-ID:
3087631
Licences
License:
CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:
http://creativecommons.org/licenses/by-nc/4.0/
Description:
A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Secondary language
Language:
Slovenian
Keywords:
farmacevtska kemija
,
prolinovi analogi
,
monoklonska protitelesa
,
subkutana aplikacija
,
sredstva za zmanjševanje viskoznosti
,
visoka koncentracija
Projects
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
P1-0189
Name:
Farmacevtska tehnologija: od dostavnih sistemov učinkovin do terapijskih izidov zdravil pri otrocih in starostnikih
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
L1-3160
Name:
Razvoj visokokoncentriranih proteinskih formulacij in vrednotenje kinetike absorpcije po subkutani aplikaciji
Funder:
Other - Other funder or multiple funders
Funding programme:
Novartis d.o.o.
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back